SCHEMBL723337

SCHEMBL723337

COc1cc(-c2cc3nccc(-c4ccc(OC5CCOCC5)nc4)c3o2)cc(OC)c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.43
PIK3R1 P27986 1/20 0.43
SYK P43405 3/20 0.41
FYN P06241 3/20 0.41
PDE4C Q08493 2/20 0.38
TBK1 Q9UHD2 2/20 0.38
TGFBR1 P36897 3/20 0.35
ACVR1 Q04771 3/20 0.35
ACVR1B P36896 1/20 0.35
KCNH2 Q12809 1/20 0.35
GAK O14976 1/20 0.35
CSF1R P07333 1/20 0.35
PDGFRB P09619 1/20 0.35
KIT P10721 1/20 0.35
PDGFRA P16234 1/20 0.35
FLT3 P36888 1/20 0.35
CLK2 P49760 1/20 0.35
MAP2K5 Q13163 1/20 0.35
CACNB4 O00305 1/20 0.35
CACNA1A O00555 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725087 0.85 FYN (0.53) FYNPDE4CTGFBR1PDGFRBPDGFRA
SCHEMBL15210592 0.79 PDE4C (0.45) SYKFYNPDE4CTGFBR1GAK
SCHEMBL723093 0.79 PDE4C (0.55) SYKFYNPDE4C
SCHEMBL722440 0.77 PDE4C (0.43) SYKFYNPDE4CTGFBR1GAK
SCHEMBL722596 0.76 PDE4C (0.50) SYKFYNPDE4C
SCHEMBL16638610 0.76 PDE4C (0.47) SYKPDE4C
SCHEMBL10267299 0.75 MAPK1 (0.55) SYKPDE4CPDGFRB
SCHEMBL722937 0.75 FYN (0.48) SYKFYNPDE4CTGFBR1
SCHEMBL723624 0.75 PDE4C (0.47) SYKFYNPDE4C
SCHEMBL722839 0.75 PDE4C (0.51) SYKFYNPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PIK3CA 1186/4885PIK3R1 318/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.